GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (STU:8AK) » Definitions » Cyclically Adjusted PB Ratio

Alkermes (STU:8AK) Cyclically Adjusted PB Ratio : 2.76 (As of May. 23, 2024)


View and export this data going back to . Start your Free Trial

What is Alkermes Cyclically Adjusted PB Ratio?

As of today (2024-05-23), Alkermes's current share price is €22.20. Alkermes's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €8.05. Alkermes's Cyclically Adjusted PB Ratio for today is 2.76.

The historical rank and industry rank for Alkermes's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:8AK' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.65   Med: 4.46   Max: 15.13
Current: 2.75

During the past years, Alkermes's highest Cyclically Adjusted PB Ratio was 15.13. The lowest was 1.65. And the median was 4.46.

STU:8AK's Cyclically Adjusted PB Ratio is ranked worse than
63.65% of 685 companies
in the Drug Manufacturers industry
Industry Median: 1.9 vs STU:8AK: 2.75

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Alkermes's adjusted book value per share data for the three months ended in Mar. 2024 was €6.823. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €8.05 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alkermes Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Alkermes's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Cyclically Adjusted PB Ratio Chart

Alkermes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.56 2.45 2.68 2.82 3.13

Alkermes Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.01 3.29 2.92 3.13 3.08

Competitive Comparison of Alkermes's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Alkermes's Cyclically Adjusted PB Ratio falls into.



Alkermes Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Alkermes's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=22.20/8.05
=2.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Alkermes's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6.823/120.9901*120.9901
=6.823

Current CPI (Mar. 2024) = 120.9901.

Alkermes Quarterly Data

Book Value per Share CPI Adj_Book
201406 6.830 100.773 8.200
201409 7.084 100.474 8.531
201412 7.678 99.576 9.329
201503 8.839 99.975 10.697
201506 8.349 100.573 10.044
201509 8.127 100.274 9.806
201512 8.006 99.676 9.718
201603 7.519 99.676 9.127
201606 7.305 101.072 8.745
201609 7.100 100.274 8.567
201612 7.522 99.676 9.130
201703 7.429 100.374 8.955
201706 6.963 100.673 8.368
201709 6.479 100.474 7.802
201712 6.599 100.075 7.978
201803 6.048 100.573 7.276
201806 6.384 101.072 7.642
201809 6.347 101.371 7.575
201812 6.610 100.773 7.936
201903 6.217 101.670 7.398
201906 6.147 102.168 7.279
201909 6.158 102.268 7.285
201912 6.192 102.068 7.340
202003 6.063 102.367 7.166
202006 5.929 101.769 7.049
202009 5.786 101.072 6.926
202012 5.511 101.072 6.597
202103 5.512 102.367 6.515
202106 5.650 103.364 6.613
202109 5.763 104.859 6.650
202112 6.080 106.653 6.897
202203 5.983 109.245 6.626
202206 6.234 112.779 6.688
202209 6.411 113.504 6.834
202212 5.994 115.436 6.282
202303 5.656 117.609 5.819
202306 7.098 119.662 7.177
202309 7.619 120.749 7.634
202312 6.605 120.749 6.618
202403 6.823 120.990 6.823

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alkermes  (STU:8AK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Alkermes Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Alkermes's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkermes (STU:8AK) Business Description

Industry
Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Alkermes (STU:8AK) Headlines

No Headlines